Dronabinol/cannabidiol - GW Pharmaceuticals

Drug Profile

Dronabinol/cannabidiol - GW Pharmaceuticals

Alternative Names: GWP-42002/GWP-42003; GWP-42002:GWP-42003; GWP-42003/GWP-42002; GWP-42003:GWP-42002

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GW Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Preclinical Glioma

Most Recent Events

  • 07 Dec 2015 Dronabinol/cannabidiol - GW Pharmaceuticals receives Orphan Drug status for Glioma in USA prior to December 2015
  • 01 May 2014 Preclinical trials in Glioma in United Kingdom (unspecified route)
  • 31 Oct 2013 Phase-I/II clinical trials in Glioblastoma in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top